Summary: The FDA changed the FUZEON prescribing information to help avoid this common and unpleasant side effect of the drug.
On January 31 the FDA announced that the FUZEON (enfuvirtide) package insert had been changed to include precautions to avoid injection-site reactions, either using a needle, or the Biojector(r) 2000 needlefree injection system. For example, here is one place where changes were made (this is from the new version):
“Patients and caregivers should be instructed on the preferred anatomical sites for administration (upper arm, abdomen, anterior thigh). FUZEON should not be injected near any anatomical areas where large nerves course close to the skin, such as near the elbow, knee, groin or the inferior or medial sections of the buttocks, skin abnormalities, including directly over a blood vessel, into moles, scar tissue, bruises, or near the navel, surgical scars, tattoos or burn sites.”
The changes are at:
And the complete revised prescribing information is at:
Return to home page: www.aidsnews.org
Free subscription to announcements online: send a blank email to email@example.com — and reply to the email request from Yahoo to confirm your subscription. You will receive about five emails or fewer per month and can leave the list at any time. Or just visit www.aidsnews.org to read the articles — no subscription or registration required.
Copyright 2007 by John S. James. We prefer that you link to www.aidsnews.org or a specific article — no permission required. Otherwise permission is granted for nonprofit use. Please check with us (firstname.lastname@example.org) before copying articles more than a year old.